This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Carbimazole and pancreatitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Carbimazole: risk of acute pancreatitis

  • if acute pancreatitis occurs during treatment with carbimazole, immediately and permanently stop treatment. Re-exposure to carbimazole may result in life-threatening acute pancreatitis with a decreased time to onset

Advice for healthcare professionals:

  • cases of acute pancreatitis have been reported very infrequently during treatment with carbimazole
  • if acute pancreatitis occurs, stop carbimazole treatment immediately
  • do not use carbimazole in patients with a history of acute pancreatitis in association with previous treatment
  • re-exposure may result in life-threatening acute pancreatitis with a decreased time to onset
  • report suspected adverse drug reactions to the Yellow Card Scheme immediately

Reference:

  • MRHA (February 2019). Drug Safety Update 12(7):1-8.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.